Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma

Inclusion Criteria

• •Participants must meet all of the following criteria:
• •1. Age ≥18 years at the time of treatment initiation.
• •2. Histologically or pathologically confirmed diffuse large B-cell lymphoma (DLBCL).
• •3. Patients with primary refractory disease or early relapse, defined as:
• •Failure to achieve complete response (CR) after at least 4 cycles of first-line induction therapy, or
• •Relapse confirmed by imaging within 12 months after achieving CR following first-line therapy.
• •4. Patients who plan to initiate a glofitamab-containing treatment regimen (either monotherapy or combination therapy) within 12 months after study initiation.
• •5. Willing and able to comply with study follow-up and data collection requirements.